Although the COVID-19 outbreak has (temporarily) held back Zenicor"s new sales and uncertainity is still high, the first month of Q3 offered an uptick in activity with a new large contract in the UK being signed. The majority of Zenicor"s sales are recurring and the cost base has proven to be flexible, and we do not believe there should be any long-term negative effects once the pandemic crisis is over.

Link to the analysis